Soligenix (NASDAQ:SNGX) Stock Turns Volatile After The Key Data
Soligenix (NASDAQ:SNGX) jumped 11% following the grant of the orphan drug designation from the FDA for its active product candidate hypericin in T-cell lymphoma treatment. The grant expands the company’s prior orphan drug designation for the active ingredient that permitted its uses in cutaneous T-Cell lymphoma treatment. For Soligenix shareholders, this is great news as the designation grant will open up hypericin for a broader market. Besides broader market access,…